Long-term titrated-dose α-glucosidase inhibition in non-insulin- requiring Hispanic NIDDM patients

Diabetes Care

Volumn 21, Issue 3, 1998, Pages 409-415

  Johnston, Peter S ^a,d   Feig, Peter U ^a   Coniff, Robert F ^a   Krol, Alice ^a   Davidson, Jaime A ^b   Haffner, Steven M ^c  

^a BAYER CORPORATION   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^d PURDUE PHARMA L P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; MIGLITOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; HEMOGLOBIN DETERMINATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING;

ALBUMINURIA; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; CREATININE; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG EVALUATION; ENZYME INHIBITORS; FEMALE; GLUCOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HISPANIC AMERICANS; HUMANS; IMINO PYRANOSES; INSULIN; LIPIDS; MALE; MIDDLE AGED; PLACEBOS; POSTPRANDIAL PERIOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031912759     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.3.409     Document Type: Article

References (20)

1. Davidson JA, Seltzer HS, Bressler PE: Diabetes in United States Latinos: more than a growing concern. Clin Diabetes 12:119-123, 1994
2. Flegal KM, Ezzati TM, Harris MI, Haynes SG, Juarez RZ, Knowler WC, Perez-Stable EJ, Stern MP: Prevalence of diabetes in Mexican Americans, Cubans, and Puerto Ricans from the Hispanic Health and Nutrition Examination Survey, 1982-1984. Diabetes Care 14:628-638, 1991
3. Stern MP, Haffner SM: Type II diabetes and its complications in Mexican Americans. Diabetes Metab Rev 6:29-45, 1990
4. Rowe DJF, Dawnay A, Watts GF: Microalbuminuria in diabetes mellitus: review and recommendations for the measurement of albumin in urine. Ann Clin Biochem 27:297-312, 1990
5. Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, Pi-Sunyer FX, Krol A: Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 17:20-29, 1994
6. Coniff RF, Johnston PS, Krol A: Long-term effects of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in NIDDM patients treated with maximum-dose sulfonylurea (Abstract). Diabetes 45 (Suppl. 2):221A, 1996
7. Schnack C, Röggler G, Luger A, Schernthaner G: Effects of the α-glucosidase inhibitor 1-desoxynojirimycin (BAY m 1099) on postprandial blood glucose, serum insulin, and C-peptide levels in type II diabetic patients. Eur J Clin Pharmacol 30:417-419, 1986
8. Fontbonne A, Charles MA, Thibault N, Richard JL, Claude JR, Warnet JM, Rosselin GE, Eschwege E: Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 34:356-361, 1991
9. Leahy JL: Impaired β-cell function with chronic hyperglycemia: "overworked β-cell" hypothesis. Diabetes Rev 4:298-319, 1996
10. Parving HH, Noer I, Decken T, Evrin PE, Nielsen SL, Lyngsoe J, Mogensen CE, Rorth M, Svendsen PA, Trap-Jensen J, Lassen NA: The effect of metabolic regulation on microvascular permeability to small and large molecules in short-term juvenile diabetes. Diabetologia 12:161-166, 1976
11. Vasquez B, Flock EV, Savage PJ, Nagulesparan M, Bennion LJ, Baird HR, Bennett PH: Sustained reduction of proteinuria in type 2 diabetes following diet-induced reductions of hyperglycemia. Diabetologia 26:127-133, 1984
12. Schnack C, Prager RJF, Winkler J, Klauser RM, Schneider BG, Schernthaner G: Effects of 8-wk glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care 12:537-543, 1989
13. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
14. Davidson JA: Practical aspects of diabetes management: diabetes in minorities. In Diabetes in Minorities. Davidson JA, Ed. New York, HP Publishing, 1987, p. 2-13
15. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
16. Richard P, Nilsson B-Y, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
17. Hanis CL, Chu H-H, Lawson K, Hewett-Emmett D, Barton SA, Schull WJ, Garcia CA: Mortality of Mexican Americans with NIDDM: retinopathy and other predictors in Starr County, Texas. Diabetes Care 16:82-89, 1993
18. U.K. Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
19. Hoffman J, Spengler M: Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients: the Essen Study. Diabetes Care 17:561-566, 1994
20. Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TMS: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Int Med 121:928-935, 1994